Previous page

The Vivomicx team

Our experienced interdisciplinary Management Team has an outstanding track record in both business & academia.

It is our strong conviction at Vivomicx that the issue is in the tissue. We select subsets of cells in the tissue to enable detailed analytics on small amounts of homogeneous cells; contrary to whole tissue analysis. This enables us to generate a clear and unbiased picture of the molecular signature in those cells. We have proven that different subsets of cells in tissue have different molecular signatures, a fact that might be expected but hardly ever has been shown. This allows for a much more targeted approach of the onset of disease.

With our trusted partners we generate various datasets on the different subsets of cells like transcriptomics, proteomics & mRNA & miRNA read outs. These insight we utilise to generate biomarkers for diseases. We are working on projects in Renal disease, Oncology & Sepsis.

The biomarkers we generate are typically used for early diagnostics and/or therapeutic intervention.

Dr. Siert Bruins, Chief Executive Officer

Siert Bruins, CEO VivomicxSiert Bruins is trained in Medical Biology and a with a PhD in Immunopathology and Microscopy he has more than 20 years of experience in the field of putting innovative technology developed in life sciences and clinical research into business. With a fascination for turning creative technology concepts into practice he is committed to bring the Vivomicx technology to clinical application.



tel. +31 6 23651327

Jan W. Zuidema, Chief Business Officer

Jan Zuidema, CBO VivomicxJan Zuidema has a Bachelor degree in Business and an MBA in Marketing. He has over 20 years of experience in Marketing, Sales & business development of high tech products and services. Jan is an allround professional with a passion for life sciences and a drive towards collaboration and commercialization. Check the LinkedIn profile of Jan.


tel. +31 6 21124552

Prof. dr. Grietje Molema, Chief Scientific Officer

Grietje Molema, CSO VivomicxGrietje Molema, PhD, studied pharmaceutical sciences and specialized in pharmacology during her Master, PhD and postdoctoral training.  Her research interests focuses on creating a better understanding of microvascular behavior in health and disease by studying microvessels in the complexity of tissues in which they reside. ‘The drug development process is slowed down by using too many artificial systems that have no relation with the in vivo behavior of cells. Unmasking the molecular determinants of cell behavior and true pharmacological effects in tissues is the challenge of this century with an enormous profit for mankind when successfully accomplished’. Meet Grietje and her research group.

The history of Vivomicx

In 2006, the initiative was born to found a company aimed at making the process of drug discovery more efficient. In 2006 and 2007 the initiative was tested and a grant from the Dutch government (STW, foundation for Technology & Science) was obtained to perform a feasibility study. 

In July 2008 a follow - up project was granted that enables the execution of a proof of concept study in order to further expand application of the Vivomicx technology.

The proof of concept study of the follow-up grant from STW is supported by two reputable companies who would like their clinical compound tested according to the Vivomicx method to get additional information regarding the pharmacological behaviour of the compounds that are in the clinical test phase.

In October 2006, the commercial entity Vivomicx was registered at the Chamber of Commerce in Groningen. In the beginning of 2008, the predecessor of Vivomicx, the laboratory of Endothelial Biomedicine & Vascular Drug Targeting Research at the University Medical Center of Groningen (UMCG) received a request from Genmab to carry out a target validation study on human tumor material. The results of that target validation study have been provided to Genmab after which we received back a reaction that expressed great customer satisfaction.

Vivomicx: Better drugs faster